Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Silverchair Information Systems full text link Silverchair Information Systems Free PMC article
Full text links

Actions

Share

.2006 Apr 17;203(4):871-81.
doi: 10.1084/jem.20050930. Epub 2006 Apr 10.

B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma

Affiliations

B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma

Ilona Kryczek et al. J Exp Med..

Abstract

Tumor-associated macrophages are a prominent component of ovarian cancer stroma and contribute to tumor progression. B7-H4 is a recently identified B7 family molecule. We show that primary ovarian tumor cells express intracellular B7-H4, whereas a fraction of tumor macrophages expresses surface B7-H4. B7-H4+ tumor macrophages, but not primary ovarian tumor cells, suppress tumor-associated antigen-specific T cell immunity. Blocking B7-H4-, but not arginase-, inducible nitric oxide synthase or B7-H1 restored the T cell stimulating capacity of the macrophages and contributes to tumor regression in vivo. Interleukin (IL)-6 and IL-10 are found in high concentrations in the tumor microenvironment. These cytokines stimulate macrophage B7-H4 expression. In contrast, granulocyte/macrophage colony-stimulating factor and IL-4, which are limited in the tumor microenvironment, inhibit B7-H4 expression. Ectopic expression of B7-H4 makes normal macrophages suppressive. Thus, B7-H4+ tumor macrophages constitute a novel suppressor cell population in ovarian cancer. B7-H4 expression represents a critical checkpoint in determining host responses to dysfunctional cytokines in ovarian cancer. Blocking B7-H4 or depleting B7-H4+ tumor macrophages may represent novel strategies to enhance T cell tumor immunity in cancer.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Ovarian tumor cells express intracellular B7-H4. B7-H4 expression was analyzed by RT-PCR and FACS in (a) fresh primary ovarian tumor cells and (b) ovarian tumor cell lines. FACS results expressed the mean percentage of B7-H4–expressing cells. OC8, OC21, and OC38 are three established ovarian tumor cell lines. Fresh primary ovarian tumor cells were isolated and sorted from ascites and tumor tissues with a phenotype of lin−EpCam+CD45−CD14−. Two of six representative patient samples are shown for panel a. Three of eight cell lines are shown for panel b. Filled histogram, B7-H4 expression; open histogram, isotype control.
Figure 2.
Figure 2.
Tumor-associated macrophages express B7-H4. (a and b) Tumor ascites macrophages express B7-H4. FACS analysis showed that ascites macrophages, but not control nonmalignant ascites macrophages, or fresh normal blood monocytes expressed B7-H4. Results are expressed as the mean of the percentage of B7-H4+ cells ± SEM in total macrophages. Filled histogram, B7-H4 staining; open histogram, isotype control. (c) High prevalence of B7-H4+ tumor macrophages in tumor ascites. FACS analysis was used to determine the prevalence of B7-H4+ tumor macrophages and CD3+CD4+CD25+ cells in tumor ascites (*, P < 0.001). Results are expressed as the mean of percentage ± SEM in tumor ascites mononuclear cells. (d and e) Tumor tissues were stained with anti–human B7-H4, anti–human CD3, anti–human-Ham56, and control antibody as described in Materials and methods, and analyzed with confocal microscope. (d) Tumor mass macrophages and tumor cells express B7-H4. B7-H4, green; Ham56, red. Tumor macrophages are identified as Ham56+ cells (red). Ham56+B7-H4+ cells are yellowish. Large numbers of tumor macrophages form a barrier surrounding tumor islets. (e) Tumor-infiltrating T cells are B7-H4−. Tumor cells, but not CD3+ T cells (red), expressed B7-H4 (green). 1 of 60 representative patient samples is shown for panels d and e.
Figure 3.
Figure 3.
Tumor ascites IL-6 and IL-10 stimulate macrophage B7-H4 expression. (a) Tumor ascites stimulated macrophage B7-H4 expression. Fresh normal blood monocytes were cultured 72 h with ovarian tumor ascites in the presence or absence of anti–human IL-6 or anti–human IL-10 antibodies. B7-H4 expression was analyzed by FACS. Results are expressed as the mean of B7-H4+ cell percentage ± SEM in total macrophages. (b) High concentrations of IL-6 and IL-10 in tumor ascites were detected by ELISA. (c) Recombinant IL-6 or IL-10 stimulated macrophage B7-H4 protein in a dose-dependent manner after a 72 h culture. B7-H4 expression was analyzed by FACS. Results are expressed as the mean of B7-H4+ cell percentage ± SEM in total macrophages. (d and e) Recombinant IL-4 and GM-CSF reduced macrophage B7-H4 mRNA and protein induction. Fresh blood monocytes were cultured with different concentrations of cytokines. (d) B7-H4 mRNA was detected by RT-PCR at 24 h. (e) B7-H4 surface protein was detected by FACS at 72 h. One of seven independent experiments is shown.
Figure 4.
Figure 4.
Tumor macrophages suppress TAA-specific T cell immunity in vitro. (a–e) Autologous tumor ascites CD3+CD25− T cells were stimulated with Her-2/neu peptide-loaded MDC (TAA-MDC) as described in Materials and methods. (a) Tumor T cell proliferation was detected by [3H]thymidine incorporation (CPM). Results are expressed as the mean of cpm ± SEM. TAA-specific T cell IFN-γ (b and c) and IL-2 (b and d) production was detected by intracellular staining (FACS) and ELISA. (e) Tumor macrophages inhibited Her-2/neu–specific T cell cytotoxicity. MDC-activated Her-2/neu–specific T cells were effector cells, and Her-2/neu peptide-loaded T2 cells were target cells. Her-2/neu–specific cytotoxicity was determined by FACS (see Materials and methods). Tumor macrophage to TAA-MDC ratio was 1:1 for panels b–e. (f) B7-H4+ tumor macrophages significantly suppress T cell proliferation. B7-H4+ or B7-H4− tumor macrophages were sorted from malignant ascites using a FACSaria. Normal macrophages were from M-CSF–treated normal peripheral blood monocytes. Tumor ascites CD3+ T cells were stimulated with anti-CD3 antibody and blood monocytes for 3 d in the presence of different concentrations of tumor macrophages or normal macrophages. T cell proliferation was detected by [3H]thymidine incorporation. Results are expressed as the mean of cpm ± SEM. TAM, tumor macrophages; macrophage, MΦ.
Figure 5.
Figure 5.
Blockade of B7-H4 improved macrophage-mediated T cell activation. (a and b) B7-H4–blocking oligos reduced macrophage B7-H4 expression. Fresh blood monocytes were exposed to B7-H4–blocking oligos and control oligos with medium, tumor ascites, and IL-10. (a) B7-H4 mRNA was detected at 24 h by RT-PCR with serial dilutions of cDNA. (b) B7-H4 protein was detected at 72 h by FACS. One of nine independent experiments is shown. (c and d) Blockade of B7-H4 improved tumor ascites-conditioned macrophage-mediated T cell activation in vitro. Tumor ascites-conditioned macrophages were previously treated with B7-H4–blocking oligos or control oligos and were subsequently subject to activating T cells for 72 h. (c) T cell proliferation was measured by [3H]thymidine incorporation. Results are expressed as the mean of cpm ± SEM. (d) Cell cycle in T cells was analyzed by FACS. Results are expressed as the mean of the percentage of T cells ± SEM in each cycle phase. The ratio between macrophages and T cells was 1:1 for panel d.n = 4–8; *, P < 0.05 compared with control oligos.
Figure 6.
Figure 6.
B7-H4+ macrophages mediate an immunosuppression independent of B7-H1, arginase, and iNOS. (a) B7-H1, arginase, and iNOS expression on tumor ascites-associated macrophages. B7-H1 expression was analyzed by FACS. Arginase I and iNOS expression was detected by Western blot. A, B, C, D, and E represent 5 individual patients with ovarian cancer. (b) Tumor ascites-conditioned macrophages mediated T cell suppression through B7-H4. T cells were stimulated with tumor ascites-conditioned macrophages for 72 h in the presence of the indicated conditions. T cell proliferation was measured by [3H]thymidine incorporation in the last 16 h. The results were expressed as the percentage of suppression (mean ± SEM). The ratio between macrophages and T cells was 1:2 for panel d.n = 5; *, P < 0.05.
Figure 7.
Figure 7.
Forced B7-H4 expression confers suppressive capacity of normal macrophages. Fresh blood monocytes were transfected using a plasmid encoding human B7-H4 or EGFP cDNA or control plasmid carried the reversed cDNA sequence of B7-H4. (a) 20 h after transfection, B7-H4 and GFP expression were detected by FACS. One of five experiments is shown. (b) Different concentrations of the transfected cells were added into T cell culture in the presence of anti–human CD3 and normal monocytes. T cell proliferation was detected by [3H]thymidine incorporation on day 3. One of five experiments is shown.
Figure 8.
Figure 8.
Blockade of B7-H4 improved macrophage-mediated T cell activation in vivo. (a) Blocking tumor ascites-conditioned macrophage B7-H4 results in tumor regression in vivo. Mice were injected with human primary ovarian tumors as described in Materials and methods. Controls received no additional injection (▴, group 1). Treatments were tumor-specific T cells plus B7-H4–blocking oligo-treated macrophages (◯, group 2), and tumor-specific T cells plus control oligo-treated macrophages (▪, group 3). Mean ± SD of tumor volumes is shown (n = 5–7 mice per group). The T cell injection day was counted as day 0. Macrophage, MΦ. (b) Macrophages and T cell were colocalized in tumor tissue. Similar results were observed in group 2 and 3. Macrophages were identified as Ham56+ cells (green) and T cells as CD3+ cells (red).n = 5.
See this image and copyright information in PMC

Comment in

  • New battlefields for costimulation.
    Martin-Orozco N, Dong C.Martin-Orozco N, et al.J Exp Med. 2006 Apr 17;203(4):817-20. doi: 10.1084/jem.20060219. Epub 2006 Apr 10.J Exp Med. 2006.PMID:16606678Free PMC article.Review.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Spiotto, M.T., P. Yu, D.A. Rowley, M.I. Nishimura, S.C. Meredith, T.F. Gajewski, Y.X. Fu, and H. Schreiber. 2002. Increasing tumor antigen expression overcomes “ignorance” to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity. 17:737–747. - PubMed
    1. Yu, P., Y. Lee, W. Liu, R.K. Chin, J. Wang, Y. Wang, A. Schietinger, M. Philip, H. Schreiber, and Y.X. Fu. 2004. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat. Immunol. 5:141–149. - PubMed
    1. Singh, S., S.R. Ross, M. Acena, D.A. Rowley, and H. Schreiber. 1992. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J. Exp. Med. 175:139–146. - PMC - PubMed
    1. Perdrizet, G.A., S.R. Ross, H.J. Stauss, S. Singh, H. Koeppen, and H. Schreiber. 1990. Animals bearing malignant grafts reject normal grafts that express through gene transfer the same antigen. J. Exp. Med. 171:1205–1220. - PMC - PubMed
    1. Zou, W. 2005. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer. 5:263–274. - PubMed

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full text links
Silverchair Information Systems full text link Silverchair Information Systems Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp